COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
NCT ID: NCT00273052
Last Updated: 2018-06-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
514 participants
INTERVENTIONAL
2006-01-05
2007-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
NCT00123903
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
NCT00537043
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
NCT00347360
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
NCT00624065
Sarpogrelate Drug Interaction
NCT02097511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carvedilol Phosphate modified release formulation
Carvedilol Phosphate modified release formulation
metoprolol succinate
metoprolol succinate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carvedilol Phosphate modified release formulation
metoprolol succinate
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triglycerides of 120-400 mg/mL
* LDLc levels not requiring lipid lowering medication.
Exclusion Criteria
* Has taken any non-ocular beta-blockers within three months before screening.
* Has Type I or II diabetes.
* Taking lipid lowering medications.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Montgomery, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Fayetteville, Arkansas, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Carmichael, California, United States
GSK Investigational Site
Healdsburg, California, United States
GSK Investigational Site
Irvine, California, United States
GSK Investigational Site
La Jolla, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Poway, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Spring Valley, California, United States
GSK Investigational Site
Stockton, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Vista, California, United States
GSK Investigational Site
Avon, Connecticut, United States
GSK Investigational Site
Altamonte Springs, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Pembroke Pines, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Roswell, Georgia, United States
GSK Investigational Site
Aurora, Illinois, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Gillespie, Illinois, United States
GSK Investigational Site
Vernon Hills, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Bossier City, Louisiana, United States
GSK Investigational Site
Auburn, Maine, United States
GSK Investigational Site
Natick, Massachusetts, United States
GSK Investigational Site
Taunton, Massachusetts, United States
GSK Investigational Site
West Yarmouth, Massachusetts, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
Brooklyn Center, Minnesota, United States
GSK Investigational Site
Olive Branch, Mississippi, United States
GSK Investigational Site
Springfield, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Henderson, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Brick, New Jersey, United States
GSK Investigational Site
Elizabeth, New Jersey, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
East Syracuse, New York, United States
GSK Investigational Site
Endwell, New York, United States
GSK Investigational Site
Fishkill, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Statesville, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Kettering, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Erie, Pennsylvania, United States
GSK Investigational Site
Warminster, Pennsylvania, United States
GSK Investigational Site
West Chester, Pennsylvania, United States
GSK Investigational Site
Columbia, South Carolina, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Hartsville, South Carolina, United States
GSK Investigational Site
Simpsonville, South Carolina, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Kingsport, Tennessee, United States
GSK Investigational Site
Corpus Christi, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
Burke, Virginia, United States
GSK Investigational Site
Galax, Virginia, United States
GSK Investigational Site
Manassas, Virginia, United States
GSK Investigational Site
Newport News, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Springfield, Virginia, United States
GSK Investigational Site
Virginia Beach, Virginia, United States
GSK Investigational Site
Walla Walla, Washington, United States
GSK Investigational Site
Lewisburg, West Virginia, United States
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Newmarket, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Sarnia, Ontario, Canada
GSK Investigational Site
Gatineau, Quebec, Canada
GSK Investigational Site
Mirabel, Quebec, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Ponce, , Puerto Rico
GSK Investigational Site
Rio Piedras, , Puerto Rico
GSK Investigational Site
Río Grande, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COR103561
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.